ClinicalTrials.gg

Program

SMUP-IA-01(low-dose)

Also written as “SMUP-IA-01(mid-dose)”, “SMUP-IA-01(high-dose)” and “SMUP-IA-01(low dose)”.

Its studies are mostly in Osteoarthritis, Knee, led by Medipost.

Furthest: phase 2, since Dec 12, 20214 company-led studies, 2 open or runningNext primary completion: Mar 20, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Medipost42 open or runningphase 2since Dec 12, 2021Jul 17, 2019Mar 20, 2027phase 2 · NCT06798727

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 17, 2019First study: phase 1 study in Osteoarthritis, KneeFirst studyNCT04037345 · 12 enrolled · Korea, Republic of
  2. Apr 6, 2020Phase 1 study in Osteoarthritis, KneeNCT04339504 · 12 planned · Korea, Republic of
  3. Dec 12, 2021Phase 2 study in Osteoarthritis, KneeNCT05182034 · 94 enrolled · Korea, Republic of
  4. Jan 23, 2025Phase 2 study in Osteoarthritis, KneeNCT06798727 · 84 enrolled · Korea, Republic of

Ahead

  1. Mar 20, 2027Primary completion: phase 2 study in Osteoarthritis, KneeNCT06798727

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06798727Osteoarthritis, Knee · Korea, Republic of2Active, not recruitingMar 20, 202784
NCT05182034Osteoarthritis, Knee · Korea, Republic of2CompletedOct 17, 202394
NCT04339504Osteoarthritis, Knee · Korea, Republic of1RecruitingDec 202512
NCT04037345Osteoarthritis, Knee · Korea, Republic of1CompletedNov 12, 202012

How it is read

Names in the registry

  • “SMUP-IA-01(low-dose)”, 3 entries
  • “SMUP-IA-01(mid-dose)”, 3 entries
  • “SMUP-IA-01(high-dose)”, 2 entries
  • “SMUP-IA-01(low dose)”, 1 entry
  • “SMUP-IA-01(mid dose)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.